Related Experiment Videos
Platelet 5-HT receptor binding during depressive illness and tricyclic antidepressant treatment
P J Cowen1, E M Charig, S Fraser
1MRC Unit of Clinical Pharmacology, Littlemore Hospital, Oxford, U.K.
Journal of Affective Disorders
|July 1, 1987
Abstract:
5-Hydroxytryptamine (5-HT) receptor binding was determined in intact human platelets using 125I-iodolysergic acid diethylamide (125I-iodoLSD). The assay revealed that platelets possess a single population of specific binding sites for 125I-iodoLSD which have a high affinity for the 5-HT2 receptor antagonists, ketanserin and spiperone. There was no difference in platelet 125I-iodoLSD receptor binding between depressed patients and controls. However, treatment with tricyclic antidepressants increased the number of 125I-iodoLSD receptor binding sites without significantly altering their affinity.